Evaluation of IL 12B Genetic Polymorphism (rs3213094)

Launched by SOUTH VALLEY UNIVERSITY · Aug 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a specific genetic variation called IL 12B (rs3213094) to better understand its role in psoriasis, a long-lasting skin condition that causes red, scaly patches, often on the elbows, scalp, and lower back. Psoriasis can also affect the eyes and joints, and people with this condition often face challenges like joint pain, depression, and a higher risk of heart problems. Currently, there is no cure for psoriasis, so researchers are trying to learn more about the genetics behind it to improve future treatments.

The trial is open to adults who have had a confirmed diagnosis of severe psoriasis for at least six months. To join, participants need to have a certain level of disease severity, measured by a standard score called the PASI (Psoriasis Area and Severity Index), with more than 10% of their body affected, and also have psoriatic arthritis, which is joint inflammation related to psoriasis. People with other autoimmune diseases, pregnant or breastfeeding women, those with infections like tuberculosis or hepatitis, or those on treatments other than Humira (a medication for psoriasis) are not eligible. If you qualify and take part, you can expect to have your genetic information studied to see how it relates to your psoriasis, which may help doctors better understand and treat the condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis.
• Exclusion Criteria:
• • Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus).
• • Pregnancy and lactation.
• • Patients currently undergoing any treatment other than Humira.
• • Patients with known genetic disorders affect immune system function.
• • Patients were undergoing any treatment other than Humira in the last 6 months.
• • Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV).
• • Patients with contraindication to Humira.
• • Renal \&Vascular diseases